Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Endocyte Reports DSMB Recommendations Following Interim Futility Analysis

RELATED NEWS
Trade ECYT now with 

Endocyte, Inc. (ECYT: Quote) unveiled the outcomes of the planned independent Data Safety Monitoring Board or DSMB review of the interim futility analysis for the Phase 2b TARGET study with investigational candidate vintafolide. The DSMB urged the continuation of the vintafolide combination therapy and docetaxel monotherapy arms of the trial.

In addition, the DSMB recommended investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival or PFS at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from their investigator. The TARGET trial's top-line results are expected in early 2014.

TARGET is being conducted in non-small cell lung cancer patients with all lesions expressing the folate receptor, as determined by the investigational companion imaging agent etarfolatide. This randomized trial is fully enrolled and comprised two investigational arms, vintafolide monotherapy and vintafolide in combination with docetaxel, each of which is compared to a standard of care control arm, docetaxel monotherapy.

The primary endpoint of the trial is PFS, powered to show a 50 percent improvement in PFS compared to the control arm, while secondary endpoints include the comparison of overall response rate, overall survival and safety.

Register
To receive FREE breaking news email alerts for Endocyte, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.